Immunocore Holdings PLC IMCR
We take great care to ensure that the data presented and summarized in this overview for Immunocore Holdings plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMCR
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.06MShares$254 Million0.16% of portfolio
-
Rtw Investments, LP New York, NY4.87MShares$175 Million2.36% of portfolio
-
Wellington Management Group LLP Boston, MA4.78MShares$172 Million0.03% of portfolio
-
Primecap Management CO Pasadena, CA3.75MShares$135 Million0.11% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.8MShares$101 Million2.17% of portfolio
-
Baker Bros. Advisors LP New York, NY2.32MShares$83.5 Million0.69% of portfolio
-
Tang Capital Management LLC San Diego, CA2.31MShares$82.9 Million3.81% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.8MShares$64.7 Million2.06% of portfolio
-
Bvf Inc San Francisco, CA1.57MShares$56.6 Million3.09% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$45.5 Million0.02% of portfolio
Latest Institutional Activity in IMCR
Top Purchases
Top Sells
About IMCR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Insider Transactions at IMCR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2025
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
18,020
-100.0%
|
$720,800
$40.03 P/Share
|
|
Nov 25
2025
|
David M Berman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
18,020
+50.0%
|
$306,340
$17.46 P/Share
|
|
Nov 24
2025
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$4,000
$40.0 P/Share
|
|
Nov 24
2025
|
David M Berman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$1,700
$17.46 P/Share
|
|
Sep 30
2025
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
61,849
-100.0%
|
$2,164,715
$35.23 P/Share
|
|
Sep 30
2025
|
David M Berman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
61,849
+50.0%
|
$1,051,433
$17.46 P/Share
|
|
Sep 15
2025
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
200
-100.0%
|
$7,000
$35.01 P/Share
|
|
Sep 15
2025
|
David M Berman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+50.0%
|
$3,400
$17.46 P/Share
|
|
Sep 12
2025
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
22,532
-97.12%
|
$788,620
$35.97 P/Share
|
|
Sep 12
2025
|
David M Berman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
22,532
+50.0%
|
$383,044
$17.46 P/Share
|
|
Sep 11
2025
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
19,081
-100.0%
|
$686,916
$36.28 P/Share
|
|
Sep 11
2025
|
David M Berman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
19,081
+50.0%
|
$324,377
$17.46 P/Share
|
|
Sep 10
2025
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
31,338
-98.09%
|
$1,128,168
$36.45 P/Share
|
|
Sep 10
2025
|
David M Berman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
31,338
+50.0%
|
$532,746
$17.46 P/Share
|
|
Mar 17
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
807,338
+14.7%
|
$23,412,802
$29.65 P/Share
|
|
Apr 01
2024
|
Leger Tina Amber St CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
4,375
-100.0%
|
$280,000
$64.06 P/Share
|
|
Apr 01
2024
|
Leger Tina Amber St CHIEF HR OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,375
+50.0%
|
$126,875
$29.87 P/Share
|
|
Feb 28
2024
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
36,509
-68.63%
|
$2,519,121
$69.16 P/Share
|
|
Feb 28
2024
|
David M Berman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
36,509
+50.0%
|
$620,653
$17.46 P/Share
|
|
Feb 27
2024
|
David M Berman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
54,938
-59.61%
|
$3,845,660
$70.79 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 807K shares |
|---|---|
| Exercise of conversion of derivative security | 153K shares |
| Open market or private sale | 153K shares |
|---|